Aducanumab (BIIB037), an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double-blind, placebo controlled, phase 1b study

Authors
Category Primary study
JournalAlzheimer's and Dementia
Year 2015
This article has no abstract
Epistemonikos ID: d2ec7906a4a582e126ee065308956cfc0fcd2061
First added on: Feb 07, 2025